Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now early-phase tilt

Celiac Disease: early-phase trial registry

14 of 25 indexed Celiac Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 14 currently recruiting · #652 of 28,707 conditions by registered trial count

Celiac Disease: 25 US clinical trials tracked, 14 recruiting.

Celiac Disease is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Nielsen Fernandez-Becker, running 2 of these trials.

Enrollment posture brief

Registry condition celiac-disease

OPEN 14 | RECR 56% | LATE 0 | EARLY 10 | RANK #652 | SPON 2

Nearest open-share peer: Marginal Zone Lymphoma (56% recruiting · 50 trials)

Celiac Disease (this)56%Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%
Open-enrollment share among volume-matched conditions near Celiac Disease

Celiac Disease lists 14 open slots (56% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Celiac Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Celiac Disease is recruiting above its size-band peers.

    14 of 25 indexed trials (56%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Celiac Disease trials is spread across many organizations.

    Nielsen Fernandez-Becker accounts for 2 of 25 trials (8%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Typical Celiac Disease enrolment sits around 92 participants.

    Median target enrolment is 92 among the 25 trials that report a genuine target (sentinel values excluded). 13 of those (52%) plan for fewer than 100 participants.

  4. Celiac Disease splits between interventional and observational designs.

    16 interventional and 9 observational studies make up this index (64% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 26

Open and recent trials

25 total, page 1 of 1

RECRUITING 33,000 participants

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

Sanford Health

NCT04477928

RECRUITING 10,000 participants

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Brain Inflammation Collaborative

NCT04806620

RECRUITING 1,250 participants

Urine Metabolites in the Diagnosis of Disease

Luventix

NCT06710067

RECRUITING 500 participants

Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Massachusetts General Hospital

NCT02061306

RECRUITING NA 400 participants

Immune Responses to Gluten

Boston Children's Hospital

NCT05209568

RECRUITING 300 participants

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

TScan Therapeutics

NCT06587828

RECRUITING NA 220 participants

Tissue Destruction and Healing in Celiac Disease

University of Chicago

NCT05680012

RECRUITING 200 participants

Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

AdventHealth Translational Research Institute

NCT06908057

RECRUITING NA 200 participants

Gluten Technology and Education for Celiac Health

Columbia University

NCT06059716

RECRUITING Phase 2 92 participants

Study of DONQ52 in Active Celiac Disease

Chugai Pharmaceutical

NCT07239336

RECRUITING Phase 2 48 participants

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Teva Branded Pharmaceutical Products R&D

NCT06807463

RECRUITING Early Phase 1 45 participants

VTP-1000 in Adults With Celiac Disease

Barinthus Biotherapeutics

NCT06310291

RECRUITING Phase 2 40 participants

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Massachusetts General Hospital

NCT05636293

RECRUITING Phase 1 18 participants

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

Nielsen Fernandez-Becker

NCT07063823

ACTIVE NOT RECRUITING Phase 2 229 participants

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

Sanofi

NCT06557772

COMPLETED 500 participants

Detection of Celiac Disease in Patients With Hypothyroidism

University of Vermont

NCT01862510

COMPLETED Phase 2 153 participants

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Takeda

NCT05353985

COMPLETED NA 84 participants

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

Capso Vision

NCT04573959

COMPLETED NA 60 participants

Changes in Intestinal Permeability 4 Hours After Gluten Challenge

Mayo Clinic

NCT03288831

COMPLETED Phase 2 55 participants

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion

NCT06001177

COMPLETED 40 participants

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

Mayo Clinic

NCT02690532

COMPLETED Early Phase 1 40 participants

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

Entero Therapeutics

NCT03011931

COMPLETED NA 24 participants

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Regeneron Pharmaceuticals

NCT04614571

COMPLETED Phase 1 12 participants

PTG-100 for Patients With Celiac Disease

Nielsen Fernandez-Becker

NCT04524221

COMPLETED 12 participants

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

Chugai Pharmaceutical

NCT05686369

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6

Named interventions

Most-linked intervention names on Celiac Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Gluten Powder Dietary supplement
2 trials
Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar Dietary supplement
1 trials
TAK-062 Placebo Drug
1 trials
Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar Dietary supplement
1 trials
TAK-062 Drug
1 trials
KAN-101 Drug
1 trials
Gluten Dietary supplement
1 trials

US sites by state

Facility locations filed on Celiac Disease trials. A trial with sites in several states counts in each.

California 11 trials
Minnesota 8 trials
Massachusetts 8 trials
Florida 7 trials
Colorado 7 trials
Texas 4 trials
New York 3 trials
Michigan 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Celiac Disease page

25 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Celiac Disease condition card totals 25 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.